ECTRIMS Congress - 2018 Conference Review, reviewed by Dr. Todd Hardy

In this review:

Early MRI predictors of long-term MS outcomes
Phase 2 trial of evobrutinib in patients with RRMS
Satralizumab as add-on therapy for neuromyelitis spectrum disorder
The MS-SMART trial: amiloride vs fluoxetine vs riluzole in SPMS
Seroprevalence of Epstein-Barr virus in MS patients
Switching to natalizumab vs fingolimod after relapse on first-line therapy
Predictors of long-term cognitive function in CIS patients
Extended interval dosing of natalizumab
Characteristics of familial vs sporadic MS
Does DMT affect fertility and pregnancy outcomes?

Please login below to download this issue (PDF)